Parallel Advisors’s Orphazyme A/S ORPH Stock Holding History

Parallel Advisors’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-400	Closed	-$4K	–	2792
2020 Q3	$4K	Buy	+400	New	+$4.01K	﹤0.01%	2153

Other funds holding ORPH

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Parallel Advisors's ORPH Position: Q4 2020 in Review

Parallel Advisors sold out of Orphazyme A/S (ORPH) in Q4 2020, closing a stake of 400 shares — an estimated $4K sold.

Parallel Advisors first reported a position in ORPH in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 5 funds tracked by Wall St. Rank hold ORPH as of Q4 2020.

Parallel Advisors reported no remaining Orphazyme A/S position as of Q4 2020 after selling out during the quarter.
Parallel Advisors sold 400 Orphazyme A/S shares in Q4 2020, an estimated $4K.
Parallel Advisors first reported a position in Orphazyme A/S in Q3 2020 and held it in 1 quarter.
Parallel Advisors's Orphazyme A/S position peaked at $4K in Q3 2020.
5 funds tracked by Wall St. Rank held Orphazyme A/S as of Q4 2020.

Based on Parallel Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.